Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 8:30 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 26,636 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Hot Flashes
Interventions: Gabapentin Extended-Release (G-ER) 1200 mg, Gabapentin Extended-Release (G-ER) 1800 mg, Placebo; Drug
Lead sponsor: Depomed; Industry
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 541 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 45
States / cities: Birmingham, Alabama • Montgomery, Alabama • Tempe, Arizona + 42 more

Conditions: Gastrointestinal Stromal Tumors
Interventions: Masitinib, Imatinib; Drug
Lead sponsor: AB Science; Industry
Eligibility: 18 Years and older
Enrollment: 335 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 7
States / cities: Orlando, Florida • Atlanta, Georgia • Detroit, Michigan + 4 more

Conditions: Healthy Participants
Interventions: BMS-986278, Sildenafil, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 35 Years to 65 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 2
States / cities: Cypress, California • Miami, Florida

Conditions: Type 2 Diabetes Mellitus
Interventions: PHX1149T; Drug
Lead sponsor: Phenomix; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 22
States / cities: Chula Vista, California • Fullerton, California • Long Beach, California + 19 more

Conditions: Cocaine Dependence
Interventions: N-Acetylcysteine, Matching Placebo; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 65 Years
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, Linagliptin 5mg; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 15
States / cities: Birmingham, Alabama • Long Beach, California • North Hollywood, California + 12 more

Conditions: Down Syndrome
Interventions: Down Syndrome Clinic to You (DSC2U); Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 1 Year and older
Enrollment: 281 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Secondary Hyperparathyroidism, Chronic Kidney Disease
Interventions: Zemplar, 42 Ca carbonate absorption via single tracer method, Calcijex; Drug · Procedure
Lead sponsor: Abbott; Industry
Eligibility: 20 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Epilepsy
Interventions: USL255, Placebo; Drug
Lead sponsor: Upsher-Smith Laboratories; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 19
States / cities: Phoenix, Arizona • Ventura, California • Gainesville, Florida + 16 more

Conditions: Peptic Ulcers
Interventions: Celecoxib, Naproxen, ASA; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 50 Years to 75 Years
Enrollment: 605 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 23
States / cities: Anaheim, California • San Diego, California • Farmington, Connecticut + 19 more

Conditions: Diabetic Polyneuropathy
Interventions: Eptinezumab, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Barrett's Esophagus, Obesity
Interventions: Omega-3 polyunsaturated fatty acids, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Diabetes Mellitus
Interventions: Alogliptin, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 329 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 50
States / cities: Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 47 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®, Colecalciferol 2000 IU, Placebo; Biological · Dietary Supplement
Lead sponsor: Diamyd Medical AB; Industry
Eligibility: 12 Years to 28 Years
Enrollment: 321 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 13
States / cities: Newport Beach, California • Palo Alto, California • San Diego, California + 10 more

Conditions: Chronic Plaque Psoriasis
Interventions: Placebo, secukinumab (AIN457), etanercept; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1,306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 13
States / cities: Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 9 more

Conditions: Dental Caries
Interventions: ZR Crown, Stainless Steel Crown; Device
Lead sponsor: NuSmile, Ltd.; Industry
Eligibility: 3 Years to 7 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 2
States / cities: San Antonio, Texas

Conditions: Healthy Participants
Interventions: CK-3828136, Placebo for CK-3828136; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Alcohol Use Disorder
Interventions: Ibudilast, Placebo oral capsule; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 65 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Traumatic Brain Injury
Interventions: Armodafinil, Placebo; Drug · Other
Lead sponsor: Cephalon, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 68
States / cities: Birmingham, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 53 more

Conditions: Postoperative Respiratory Complications
Interventions: Lung protective strategy ventilation; Procedure
Lead sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); Other
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Boston, Massachusetts • Rochester, New York

Conditions: COVID-19
Interventions: Exercise Prescription; Other
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Frisco, Texas

Conditions: Head and Neck Cancer
Interventions: Guided Imagery, Treatment as Usual; Behavioral · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 100 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Dizziness, Vertigo
Interventions: Pentoxifylline, Placebo; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 40 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Generalized Epidermolysis Bullosa Simplex
Interventions: AC-203, Vehicle; Drug
Lead sponsor: TWi Biotechnology, Inc.; Industry
Eligibility: 6 Months and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 7
States / cities: Rancho Santa Margarita, California • Stanford, California • Aurora, Colorado + 4 more

Search by objective public record fields.

Study of Gabapentin Extended Release (G-ER) in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women

Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)

A Study Investigating the Safety, Tolerability, Drug Levels and Drug Effect of BMS-986278 in Healthy Adult Participants (Part 1) and Japanese Participants (Part 2)

A Study to Evaluate Safety and Efficacy of PHX1149T in Subjects With Type 2 Diabetes Mellitus

Effectiveness of N-Acetylcysteine (NAC) in Treating Cocaine Dependent Individuals - 1

MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin

An Online Health Tool About Down Syndrome: Down Syndrome Clinic to You

Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium

Study to Evaluate the Safety and Effectiveness of USL255 in Patients With Refractory Partial-onset Seizures

Celebrex Low Dose ASA Study Examining the Incidence of Gastroduodenal Ulcers in a Healthy Population

A Study of CGRP Monoclonal Antibody to Treat Diabetic Neuropathy

Modulation of Esophageal Inflammation in Barrett's Esophagus by Omega-3 Fatty Acids

Efficacy and Safety of Alogliptin in Subjects With Type 2 Diabetes

A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes

Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis

Trial of a New NuSmile ZR Esthetic Primary Molar Crown

A Single and Multiple Ascending Dose Study of CK-3828136 in Healthy Adult Participants

Ibudilast for the Treatment of Alcohol Use Disorder

Study to Evaluate the Efficacy and Safety of Armodafinil as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury

PROVHILO:Protective Ventilation During General Anesthesia for Open Abdominal Surgery

Exercise in Adults with Post-Acute Sequelae of SARS-CoV-2 (COVID-19) Infection Study

Effect of Guided Imagery for Radiotherapy-Related Distress in Patients With Head and Neck Cancer

Trental for the Treatment of Vertigo/Dizziness/Imbalance

An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)